GB201207722D0 - Method - Google Patents

Method

Info

Publication number
GB201207722D0
GB201207722D0 GB201207722A GB201207722A GB201207722D0 GB 201207722 D0 GB201207722 D0 GB 201207722D0 GB 201207722 A GB201207722 A GB 201207722A GB 201207722 A GB201207722 A GB 201207722A GB 201207722 D0 GB201207722 D0 GB 201207722D0
Authority
GB
United Kingdom
Prior art keywords
akt3
emt
epithelial
occurrence
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201207722A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BerGenBio ASA
Original Assignee
BerGenBio ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BerGenBio ASA filed Critical BerGenBio ASA
Priority to GB201207722A priority Critical patent/GB201207722D0/en
Publication of GB201207722D0 publication Critical patent/GB201207722D0/en
Priority to EP13728839.5A priority patent/EP2845004A2/en
Priority to IN2114MUN2014 priority patent/IN2014MN02114A/en
Priority to JP2015509554A priority patent/JP2015525060A/ja
Priority to CN201380023276.5A priority patent/CN104335046B/zh
Priority to US14/398,572 priority patent/US10317405B2/en
Priority to AU2013255456A priority patent/AU2013255456B2/en
Priority to PCT/IB2013/053488 priority patent/WO2013164788A2/en
Priority to EA201401201A priority patent/EA201401201A1/ru
Priority to SG11201407032WA priority patent/SG11201407032WA/en
Priority to CA2871352A priority patent/CA2871352A1/en
Priority to BR112014027219A priority patent/BR112014027219A2/pt
Priority to KR1020147032804A priority patent/KR102179389B1/ko
Priority to JP2017052865A priority patent/JP6738755B2/ja
Priority to US16/408,816 priority patent/US20200072839A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
GB201207722A 2012-05-02 2012-05-02 Method Ceased GB201207722D0 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
GB201207722A GB201207722D0 (en) 2012-05-02 2012-05-02 Method
KR1020147032804A KR102179389B1 (ko) 2012-05-02 2013-05-02 방법
AU2013255456A AU2013255456B2 (en) 2012-05-02 2013-05-02 Method
EA201401201A EA201401201A1 (ru) 2012-05-02 2013-05-02 Способ
JP2015509554A JP2015525060A (ja) 2012-05-02 2013-05-02 Ａｋｔ３関連病態の予知及び治療方法
CN201380023276.5A CN104335046B (zh) 2012-05-02 2013-05-02 方法
US14/398,572 US10317405B2 (en) 2012-05-02 2013-05-02 Methods of detecting Akt3 and administering Ax1 inhibitor
EP13728839.5A EP2845004A2 (en) 2012-05-02 2013-05-02 Method
PCT/IB2013/053488 WO2013164788A2 (en) 2012-05-02 2013-05-02 Method
IN2114MUN2014 IN2014MN02114A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2012-05-02 2013-05-02
SG11201407032WA SG11201407032WA (en) 2012-05-02 2013-05-02 Method
CA2871352A CA2871352A1 (en) 2012-05-02 2013-05-02 Use of akt3 as a biomarker for detecting the occurrence of epithelial-to-mesenchymal transition
BR112014027219A BR112014027219A2 (pt) 2012-05-02 2013-05-02 método
JP2017052865A JP6738755B2 (ja) 2012-05-02 2017-03-17 Ａｋｔ３関連病態の予知及び治療方法
US16/408,816 US20200072839A1 (en) 2012-05-02 2019-05-10 Method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201207722A GB201207722D0 (en) 2012-05-02 2012-05-02 Method

Publications (1)

Publication Number Publication Date
GB201207722D0 true GB201207722D0 (en) 2012-06-13

Family

ID=46330714

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201207722A Ceased GB201207722D0 (en) 2012-05-02 2012-05-02 Method

Country Status (13)

Country Link
US (2) US10317405B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2845004A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP2015525060A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR102179389B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN104335046B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013255456B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112014027219A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2871352A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA201401201A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB201207722D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014MN02114A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG11201407032WA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013164788A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3169801A1 (en) * 2014-07-14 2017-05-24 F. Hoffmann-La Roche AG Diagnostic methods and compositions for treatment of glioblastoma
GB201420239D0 (en) * 2014-11-14 2014-12-31 Bergenbio As Biomarker
GB201512133D0 (en) 2015-07-10 2015-08-19 Bergenbio As Biomarkers
KR101941054B1 (ko) * 2016-07-20 2019-01-23 연세대학교 산학협력단 암 예후 예측을 위한 조성물 및 이를 포함하는 키트
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
KR102080384B1 (ko) * 2018-02-28 2020-02-21 주식회사 마크로젠 암줄기세포 특이적 바이오마커
JP7612576B2 (ja) * 2018-11-12 2025-01-14 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ がんの細胞状態移行を操作するための方法
CA3182675A1 (en) * 2020-05-08 2021-11-11 Georgiamune Llc Akt3 modulators and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6809194B1 (en) 2000-05-10 2004-10-26 Chiron Corporation Akt3 inhibitors
US20040121413A1 (en) 2002-12-20 2004-06-24 Aebersold Rudolf H. Androgen-regulated genes and uses for diagnosis, prognosis and treatment of prostate neoplastic conditions
WO2004086038A2 (en) * 2003-03-28 2004-10-07 Institut Curie A method for screening compounds having the capacity to control tumor cell invasion or metastasis using constitutively active akt
JP4679514B2 (ja) * 2003-04-24 2011-04-27 メルク・シャープ・エンド・ドーム・コーポレイション Ａｋｔ活性の阻害剤
WO2008042867A2 (en) * 2006-09-29 2008-04-10 Emiliem Inc. Modulators of multiple kinases
EP2114983B8 (en) 2007-02-07 2015-02-18 The Regents of the University of Colorado, A Body Corporate Axl tyrosine kinase inhibitors and methods of making and using the same
WO2009009793A2 (en) * 2007-07-12 2009-01-15 University Of South Florida Inhibitors of akt/pkb with anti-tumor activity
EP2179037A4 (en) * 2007-08-21 2010-12-22 Nodality Inc DIAGNOSIS, FORECASTING AND TREATMENT PROCEDURES
US8735064B2 (en) 2007-12-24 2014-05-27 Bergenbio As Methods for creating and identifying functional RNA interference elements
US8067178B2 (en) 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
PL2387395T3 (pl) 2009-01-16 2015-03-31 Rigel Pharmaceuticals Inc Inhibitory Axl do zastosowania w terapii skojarzonej do zapobiegania, leczenia lub postępowania z nowotworem przerzutowym
WO2010091354A2 (en) 2009-02-06 2010-08-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Akt tyrosine 176 phosphorylation cancer biomarker
RU2586493C2 (ru) 2009-03-13 2016-06-10 Берген Текнологиоверфоринг Ас Способ применения axl в качестве маркера эпителиально-мезенхимального перехода
WO2010115119A2 (en) * 2009-04-02 2010-10-07 Tufts Medical Center, Inc. Compositions and methods for diagnosis and prognosis of cancer and progression, and for screening anti-cancer agents
WO2011050351A2 (en) 2009-10-23 2011-04-28 The Translational Genomics Research Institute Methods and kits used in identifying glioblastoma
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
EP2598659B1 (en) 2010-07-27 2015-03-11 Genomic Health, Inc. Method for using gene expression to determine prognosis of prostate cancer
US20130171159A1 (en) * 2010-09-10 2013-07-04 Brian Arthur Hemmings Phosphorylated twist1 and metastasis
US20140030255A1 (en) * 2010-11-03 2014-01-30 Merck Sharp & Dohme Corp. Methods of predicting cancer cell response to therapeutic agents

Also Published As

Publication number Publication date
AU2013255456A1 (en) 2014-11-13
US20200072839A1 (en) 2020-03-05
IN2014MN02114A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-09-04
CN104335046A (zh) 2015-02-04
WO2013164788A2 (en) 2013-11-07
JP6738755B2 (ja) 2020-08-12
AU2013255456B2 (en) 2018-07-26
CA2871352A1 (en) 2013-11-07
US10317405B2 (en) 2019-06-11
EP2845004A2 (en) 2015-03-11
BR112014027219A2 (pt) 2017-06-27
US20150119475A1 (en) 2015-04-30
WO2013164788A3 (en) 2014-01-23
KR20150016518A (ko) 2015-02-12
JP2015525060A (ja) 2015-09-03
EA201401201A1 (ru) 2015-02-27
JP2017136077A (ja) 2017-08-10
KR102179389B1 (ko) 2020-11-18
CN104335046B (zh) 2019-10-11
SG11201407032WA (en) 2014-11-27

Similar Documents

Publication Publication Date Title
GB201207722D0 (en) Method
EP2856200A4 (en) METHOD, APPARATUS AND COMPUTER FOR HIGH PRECISION LOCATION DETERMINATION
WO2010103388A3 (en) Methods using axl as a biomarker of epithelial-to-mesnchymal transition
HUE042271T2 (hu) Emberi EZH2 inhibitorai és azok alkalmazási eljárásai
HRP20181963T1 (hr) Postupci za liječenje ili sprječavanje astme primjenom antagonista il-4r
EP2836277A4 (en) COGNITIVE AND INTERACTIVE MULTISENSORY INTERFACE APPARATUS AND METHODS FOR EVALUATING ATHLETES AND OTHER CATEGORIES OF PEOPLE, ESTABLISHING PROFILES, TRAINING AND / OR IMPROVING THEIR PERFORMANCE
IL233163B (en) A system and method for detecting RNA altered by cancer in peripheral blood
EP2936411A4 (en) METHOD, SYSTEM AND DEVICE FOR SALES TRANSACTIONS
GB201121934D0 (en) Method of, and apparatus for, windowed full waveform inversion
SG11201500291TA (en) Method of and system for tracking gaming activity
MX2013010050A (es) Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus.
WO2012145399A3 (en) Methods of diagnosing cancer in a patient
GB2515009B (en) Methods of and apparatuses for improving log data
IN2012DE00794A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY157066A (en) A method for preparing an immunogen and a use thereof
GB201409114D0 (en) Method, computer program, and computer for detecting trends in social medium
NZ631749A (en) Methods of treating cancer using angiogenin or an angiogenin agonist
NZ703905A (en) Method of treating multiple sclerosis by using narrow band uvb
IN2014MN01871A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB201223288D0 (en) Apparatus, method and computer program for cell detection
GB201213969D0 (en) Method,apparatus and computer program for carrying out cell measurements
IN2014CN02496A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB201318729D0 (en) Indicator molecules for use in detecting enzyme cleavage activity
GB2502344B (en) Method, apparatus and computer program for signal to noise and interference ratio estimation
UA72228U (ru) Способ определения содержания металлов в объектах биосферы нейтронно-активационным методом

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)